Auna S.A. (AUNA) stock price is $5.42, up 0.74% on the day, as of Oct 20, 2026. It has a market cap of $401.89Mn and a P/E ratio of 14.24, and is classified in the Hospitals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap401.89 Mn
P/E14.24
P/S0.32
Div. Yield0.00
Total Debt (Qtr)1.05 Bn
Add ratio to table…
About
Auna S. A. is a healthcare company that operates hospitals and clinics and provides prepaid healthcare plans in Mexico Peru and Colombia.
The company generates revenue primarily from fees charged for hospital and clinic services such as inpatient stays outpatient visits surgeries and diagnostic tests and from membership fees for its prepaid healthcare plans in Peru and Mexico and from premiums collected for its dental vision and oncological insurance plans in Mexico.
The…
Auna S. A. is a healthcare company that operates hospitals and clinics and provides prepaid healthcare plans in Mexico Peru and Colombia.
The company generates revenue primarily from fees charged for hospital and clinic services such as inpatient stays outpatient visits surgeries and diagnostic tests and from membership fees for its prepaid healthcare plans in Peru and Mexico and from premiums collected for its dental vision and oncological insurance plans in Mexico.
The company operates through the following segments.
Healthcare Services in Mexico includes the Auna Mexico network of three high complexity hospitals in Monterrey and Auna Seguros which offers dental vision and oncological insurance plans to over 3.5 million members nationwide.
Healthcare Services in Peru comprises the Auna Peru network of hospitals clinics diagnostic imaging centers and clinical laboratories that deliver medium and high complexity care across the country.
Healthcare Services in Colombia consists of the Auna Colombia network of hospitals and clinics providing medium and high complexity services in key cities such as Medellín Barranquilla and Montería.
Oncosalud Peru offers prepaid healthcare plans focused on oncology and general health and operates dedicated oncology facilities that provide prevention detection and treatment services to plan members and third party patients.
Auna S. A. holds a leading position in the private healthcare sector of Peru where it has the largest share of prepaid oncology plans and a 25.5 percent market share among all healthcare plan providers. Its vertical integration in Peru gives it control over both coverage and care delivery which results in predictable costs and strong clinical outcomes such as a 74 percent five year cancer survival rate for its oncology members. Across Mexico and Colombia the company competes with other private hospital groups but benefits from horizontal integration that provides scale bargaining power with insurers and suppliers and enables standardized clinical protocols. Key competitors include Rímac and Pacífico in Peru hospital groups such as Christus Muguerza Hospital Angeles TecSalud and Swiss Hospital in Mexico and Colombian networks like San Vicente de Paul Pablo Tobón Uribe and El Rosario.
The company serves individual patients members of its prepaid healthcare plans employers that purchase coverage for their workers and private insurers that include its facilities in their provider networks.
Sector:HealthcareSector rationaleThe company's primary business is the operation of hospitals, clinics, and diagnostic centers across Mexico, Peru, and Colombia, providing inpatient and outpatient medical services. It also operates a substantial insurance and prepaid healthcare business (Auna Seguros and Oncosalud), which involves collecting premiums and membership fees, justifying a secondary sector in Financial Services.Industries:HospitalsHospitalsPrimaryAuna operates a network of high and medium complexity hospitals in Mexico, Peru, and Colombia, generating revenue from inpatient stays and surgeries.Managed CareManaged CareSecondaryThe company provides prepaid healthcare plans and collects premiums for dental, vision, and oncological insurance plans, particularly through Auna Seguros and Oncosalud Peru.Healthcare ServicesHealthcare ServicesSecondaryAuna operates clinics, diagnostic imaging centers, and clinical laboratories that deliver outpatient care and diagnostic tests.Classified using BQ-MICSCIK: 0001799207
Bull & bear
Investment Thesis
▲ Bull case
Auna is well-positioned for margin expansion in Mexico through operating leverage and variable cost discipline as oncology and high-complexity services scale, with the new ISSSTELEON contract enabling full control over device and pharmaceutical usage, which directly improves cost containment and supports management's target of over 20% consolidated EBITDA margin. The renegotiated contract's improved economics, combined with state-of-the-art radiotherapy equipment coming online in Monterrey within 1–1.5 months, will drive volume and margin upside that is not yet reflected in current guidance, creating a structural tailwind for profitability in the company's second-largest market. This shift toward higher-margin, complexity-driven care is being actively managed through pricing, mix optimization, and volume growth, positioning Auna to capture medical inflation and exceed it over the medium-to-long term.
The Torre Trecca project in Lima represents a significant, underappreciated catalyst for Peru's growth trajectory, with construction consortium awarded and work set to begin immediately, expanding Auna's addressable market through enhanced ambulatory and B2G capacity. Management expects completion within 18–24 months, and the project will unlock new revenue streams from high-complexity outpatient services and strengthen vertical integration, yet it received minimal promotional emphasis during the earnings call despite its strategic importance for long-term market share gains in Peru's underserved oncology and surgery segments. This infrastructure investment, funded internally with strong cash flow generation, will reduce reliance on external capacity and improve patient retention in a market where plan memberships grew 6% and oncology plans rose 3%, signaling durable demand for integrated care.
Auna's risk-sharing payer model in Colombia, now representing 21% of segment revenue (up from 15% in Q1 2025), is creating predictable top-line growth and improving cash conversion cycles, with margin pressure seen as temporary due to early-stage clinical pathway optimization and variable cost absorption as volumes scale. The company has successfully reduced exposure to intervened payers from 19% to 14%, and its unique positioning in high-complexity care ensures payer prioritization in payment lists, insulating it from broader regulatory shifts. As scale increases and clinical pathways are refined across more than 3 million covered lives, margin expansion is expected to recover the 1.7 percentage point contraction observed in Q1, driven by fixed-cost dilution and operational efficiencies that are already being realized through supplier financing initiatives and improved working capital management.
Strong free cash flow generation, up 2.6x year-over-year to PEN 152 million, supported by 45% growth in pretax operating cash flow and supplier financing initiatives in Peru, Mexico, and Colombia, is providing Auna with significant financial flexibility to fund growth investments, reduce leverage toward its 3x target, and potentially resume capital return programs despite current board deliberations on buybacks. The 22% increase in cash to PEN 409 million, combined with 55% local-currency debt and 85% hedging of USD-denominated debt, creates a resilient balance sheet that can absorb Peru-specific FX volatility while funding CapEx at 3% of revenue for infrastructure, medical equipment, and IT systems—key enablers of the vertical integration and AunaWay strategy that management believes will deliver sustained, predictable growth.
Auna is well-positioned for margin expansion in Mexico through operating leverage and variable cost discipline as oncology and high-complexity services scale, with the new ISSSTELEON contract enabling full control over device and pharmaceutical usage, which directly improves cost containment and supports management's target of over 20% consolidated EBITDA margin. The renegotiated contract's improved economics, combined with state-of-the-art radiotherapy equipment coming online in Monterrey within 1–1.5 months, will drive volume and margin upside that is not yet reflected in current guidance, creating a structural tailwind for profitability in the company's second-largest market. This shift toward higher-margin, complexity-driven care is being actively managed through pricing, mix optimization, and volume growth, positioning Auna to capture medical inflation and exceed it over the medium-to-long term.
The Torre Trecca project in Lima represents a significant, underappreciated catalyst for Peru's growth trajectory, with construction consortium awarded and work set to begin immediately, expanding Auna's addressable market through enhanced ambulatory and B2G capacity. Management expects completion within 18–24 months, and the project will unlock new revenue streams from high-complexity outpatient services and strengthen vertical integration, yet it received minimal promotional emphasis during the earnings call despite its strategic importance for long-term market share gains in Peru's underserved oncology and surgery segments. This infrastructure investment, funded internally with strong cash flow generation, will reduce reliance on external capacity and improve patient retention in a market where plan memberships grew 6% and oncology plans rose 3%, signaling durable demand for integrated care.
Auna's risk-sharing payer model in Colombia, now representing 21% of segment revenue (up from 15% in Q1 2025), is creating predictable top-line growth and improving cash conversion cycles, with margin pressure seen as temporary due to early-stage clinical pathway optimization and variable cost absorption as volumes scale. The company has successfully reduced exposure to intervened payers from 19% to 14%, and its unique positioning in high-complexity care ensures payer prioritization in payment lists, insulating it from broader regulatory shifts. As scale increases and clinical pathways are refined across more than 3 million covered lives, margin expansion is expected to recover the 1.7 percentage point contraction observed in Q1, driven by fixed-cost dilution and operational efficiencies that are already being realized through supplier financing initiatives and improved working capital management.
Strong free cash flow generation, up 2.6x year-over-year to PEN 152 million, supported by 45% growth in pretax operating cash flow and supplier financing initiatives in Peru, Mexico, and Colombia, is providing Auna with significant financial flexibility to fund growth investments, reduce leverage toward its 3x target, and potentially resume capital return programs despite current board deliberations on buybacks. The 22% increase in cash to PEN 409 million, combined with 55% local-currency debt and 85% hedging of USD-denominated debt, creates a resilient balance sheet that can absorb Peru-specific FX volatility while funding CapEx at 3% of revenue for infrastructure, medical equipment, and IT systems—key enablers of the vertical integration and AunaWay strategy that management believes will deliver sustained, predictable growth.
Auna's Peru segment faces persistent revenue recognition risks from payer reconciliation adjustments and delayed pharmaceutical rebates, which management characterizes as temporary but which recurred in Q1 and compressed EBITDA margin by 2.3 percentage points despite 9% revenue growth, suggesting structural billing inefficiencies or payer pressure that may not be fully resolved by internal cycle improvements alone, especially as insurance payers tighten controls amid rising medical loss ratios. The company's assertion that rebates are merely "delayed" and will be recognized later in the year lacks transparency on timing and magnitude, creating uncertainty about true quarterly profitability and potentially masking a trend where payer penalties become a recurring drag on Peruvian profitability, undermining the segment's ability to convert revenue growth into earnings.
Mexico's margin expansion thesis relies heavily on operating leverage from oncology and high-complexity service scaling, yet chemotherapy—a core component of oncology volumes growing at 32% sequentially—was explicitly noted by CFO Gisele Ferrero to have potentially lower margins than core hospital business, and management's confidence in margin recovery depends on unproven assumptions about radiotherapy's higher margin and the impact of new equipment, which may not materialize as expected if utilization lags or reimbursement rates face pressure from Mexico's universal health care initiative (Servicio Universal de Salud), which could shift patient volume to public facilities and compress private sector pricing power over time.
Colombia's improving risk-sharing mix, while reducing exposure to intervened payers, is currently dragging on margins due to higher variable costs associated with scaling high-complexity care under risk-sharing agreements, and the 1.7 percentage point margin contraction in Q1 may persist longer than anticipated if clinical pathway optimization fails to deliver expected cost savings, particularly as minimum wage increases (23% year-over-year) continue to elevate labor costs and the company's dependence on variable cost discipline remains unproven at scale, leaving EBITDA vulnerable to inflationary pressures in a segment where risk-sharing contracts now represent over one-fifth of revenue but have not yet demonstrated margin accretion.
Auna's leverage ratio of 3.7x, attributed to noncash FX effects, masks underlying financial strain from Peru-specific currency volatility, as the depreciation of the Peruvian sol beyond the new hedging structure's protective range more than offset the 11% operating profit increase, and while management expects reduced FX volatility going forward, the hedge reset was reactive rather than proactive, leaving the company exposed to further sol depreciation if macroeconomic conditions worsen, which could erode the 22% cash increase to PEN 409 million and pressure liquidity despite undrawn revolving credit facilities, especially if working capital improvements from supplier financing initiatives fail to sustain amid rising input costs and payer delays.
Auna's Peru segment faces persistent revenue recognition risks from payer reconciliation adjustments and delayed pharmaceutical rebates, which management characterizes as temporary but which recurred in Q1 and compressed EBITDA margin by 2.3 percentage points despite 9% revenue growth, suggesting structural billing inefficiencies or payer pressure that may not be fully resolved by internal cycle improvements alone, especially as insurance payers tighten controls amid rising medical loss ratios. The company's assertion that rebates are merely "delayed" and will be recognized later in the year lacks transparency on timing and magnitude, creating uncertainty about true quarterly profitability and potentially masking a trend where payer penalties become a recurring drag on Peruvian profitability, undermining the segment's ability to convert revenue growth into earnings.
Mexico's margin expansion thesis relies heavily on operating leverage from oncology and high-complexity service scaling, yet chemotherapy—a core component of oncology volumes growing at 32% sequentially—was explicitly noted by CFO Gisele Ferrero to have potentially lower margins than core hospital business, and management's confidence in margin recovery depends on unproven assumptions about radiotherapy's higher margin and the impact of new equipment, which may not materialize as expected if utilization lags or reimbursement rates face pressure from Mexico's universal health care initiative (Servicio Universal de Salud), which could shift patient volume to public facilities and compress private sector pricing power over time.
Colombia's improving risk-sharing mix, while reducing exposure to intervened payers, is currently dragging on margins due to higher variable costs associated with scaling high-complexity care under risk-sharing agreements, and the 1.7 percentage point margin contraction in Q1 may persist longer than anticipated if clinical pathway optimization fails to deliver expected cost savings, particularly as minimum wage increases (23% year-over-year) continue to elevate labor costs and the company's dependence on variable cost discipline remains unproven at scale, leaving EBITDA vulnerable to inflationary pressures in a segment where risk-sharing contracts now represent over one-fifth of revenue but have not yet demonstrated margin accretion.
Auna's leverage ratio of 3.7x, attributed to noncash FX effects, masks underlying financial strain from Peru-specific currency volatility, as the depreciation of the Peruvian sol beyond the new hedging structure's protective range more than offset the 11% operating profit increase, and while management expects reduced FX volatility going forward, the hedge reset was reactive rather than proactive, leaving the company exposed to further sol depreciation if macroeconomic conditions worsen, which could erode the 22% cash increase to PEN 409 million and pressure liquidity despite undrawn revolving credit facilities, especially if working capital improvements from supplier financing initiatives fail to sustain amid rising input costs and payer delays.